Curanex Pharmaceuticals (NASDAQ:CURX) Trading 0.2% Higher – Time to Buy?

Curanex Pharmaceuticals Inc (NASDAQ:CURX) shot up 0.2% during mid-day trading on Monday . The stock traded as high as $0.2979 and last traded at $0.2660. Approximately 52,317 shares were traded during mid-day trading, a decline of 39% from the average daily volume of 85,701 shares. The stock had previously closed at $0.2655.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings raised shares of Curanex Pharmaceuticals from a “sell (e)” rating to a “sell (e+)” rating in a research report on Friday, May 1st. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock presently has an average rating of “Sell”.

Curanex Pharmaceuticals Stock Up 3.4%

The company has a market cap of $7.78 million and a P/E ratio of -1.02. The firm has a fifty day moving average price of $0.34 and a 200 day moving average price of $0.37.

Curanex Pharmaceuticals (NASDAQ:CURX) last released its quarterly earnings results on Thursday, May 14th. The company reported ($0.11) earnings per share (EPS) for the quarter.

Hedge Funds Weigh In On Curanex Pharmaceuticals

An institutional investor recently bought a new stake in Curanex Pharmaceuticals stock. Citadel Advisors LLC purchased a new stake in Curanex Pharmaceuticals Inc (NASDAQ:CURX) in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 64,067 shares of the company’s stock, valued at approximately $46,000.

Curanex Pharmaceuticals Company Profile

Curanex is a developmental stage pharmaceutical company dedicated to discovering, developing and commercializing innovative botanical drugs to treat patients suffering from inflammatory diseases. Our mission is to address significant unmet medical needs and improve patients’ lives by harnessing the power of natural substances. We are dedicated to discovering, developing and commercializing botanical medicines for treating patients with immune and inflammatory diseases and to develop therapies that may offer potential benefits to patients with unmet clinical needs in various fields, such as autoimmune diseases, metabolic diseases and viral infections.